D.E.S.IR. - Epidemiological data about insulin resistance syndrome

Head :Balkau Beverley, U1018 Centre de Recherche en Epidémiologie et santé des Populations (CESP)

Last update : 01/01/2020 | Version : 3 | ID : 3520

General

Identification

Detailed name	Epidemiological data about insulin resistance syndrome
Sign or acronym	D.E.S.IR.
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	Date de réception de l'avis favorable de la CNIL : 27/05/1994

General Aspects

Medical area	Cardiology Endocrinology and metabolism
Health determinants	Genetic Nutrition
Keywords	insulin resistance syndrome, Incidence, diabetes, hypertension, dyslipidemia, cardiovascular diseases

Scientific investigator(s) (Contact)

Name of the director	Balkau
Surname	Beverley
Address	Hôpital Paul Brousse -16 av Paul Vaillant Couturier - 94807 VILLEJUIF
Phone	+33 (0)1 45 59 51 61
Email	beverley.balkau@inserm.fr
Unit	U1018 Centre de Recherche en Epidémiologie et santé des Populations (CESP)
Organization	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE -

Collaborations

Participation in projects, networks and consortia	Yes
Details	Involvement in a cohort network: DETECT-2 study, to study diabetes diagnosis criteria
Others	Other related cohorts: cameroun cohort, multiple cohorts

Funding

Funding status	Mixed
Details	Contrat Inserm-Cnamts, Inserm - réseaux en santé publique, Inserm -interactions entre les déterminants de santé, les centres d'examens de santé Cornes, TGIR 2009-2010, Novartis pharma, sanofi aventis, Association Diabète Risque vasculaire, Fédération Française de Cardiologie, La Fondation de France, Alfediam, Anivins, Ardix médical, Bayer Diagnostics, Becton Dickinson, Cardionics, Lilly France, Merck Santé, Novo Nordisk, Pierre Fabre, Roche, Topcon

Governance of the database

Sponsor(s) or organisation(s) responsible	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM
Organisation status	Public

Additional contact

Main features

Type of database

Type of database	Study databases
Study databases (details)	Longitudinal study (except cohorts)
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	Individuals inclusion mode: perspective. End of inclusions: 01/02/1996. Sample of patients consulting into Health Examination Centers

Database objective

Main objective	Describe natural history of insulin resistance syndrome and its consequences. Evaluate diabetes risk factors.
Inclusion criteria	Men and women, aged between 30 and 65, consulting in the examination centers

Population type

Age	Adulthood (25 to 44 years) Adulthood (45 to 64 years)
Population covered	Sick population
Gender	Male Woman
Geography area	Regional
French regions covered by the database	Centre-Val de Loire Pays de la Loire
Detail of the geography area	Loire valley area

Data collection

Dates

Date of first collection (YYYY or MM/YYYY)	06/1994
Date of last collection (YYYY or MM/YYYY)	2010

Size of the database

Size of the database (number of individuals)	[1000-10 000[individuals
Details of the number of individuals	5212

Data

Database activity	Data collection completed
Type of data collected	Clinical data Declarative data Paraclinical data Biological data Administrative data

Clinical data (detail)	Medical registration
Details of collected clinical data	Clinical examination at inclusion and during the follow-up. Examination frequency : 3 years. Information collected during clinical examination: blood pressure, weight, waist size, height, ECG, ankle/brachial index
Declarative data (detail)	Face to face interview
Details of collected declarative data	Clinical examination at inclusion and during the follow-up. Examination frequency : 3 years. Information collected during clinical examination: blood pressure, weight, waist size, height, ECG, ankle/brachial index
Paraclinical data (detail)	Blood pressure, ankle/brachial index, ECG, IMC, waist size, hip circumference
Biological data (detail)	Glucidic (glycemia, HbA1c, insulin) and lipid profile, transaminases, creatinine, fibrogen
Administrative data (detail)	Age, gender, birthplace
Presence of a biobank	Yes
Contents of biobank	Serum Plasma Fluids (saliva, urine, amniotic fluid, ?) DNA
Details of biobank content	On an empty stomach: plasma, serum, DNA, urine
Health parameters studied	Health event/morbidity Health event/mortality

Procedures

Data collection method	The main clinical data are collected at inclusion, then every 3 years during the follow-up (blood pressure, weight, waist circumference, size, electrocardiography (ECG), ankle-brachial pressure index). During the follow-up, the family doctor fills a questionnaire in case of a cardiovascular event. Declarative data are collected through a self-questionnaire (medicine, diet, tobacco addiction, lifestyle, diseases) at inclusion, then every year. A questionnaire has been proposed by interview (diseases, family history) at inclusion and every 3 years. Year of last data collection: 2004, examination for the participants, 2010 for death causes. Self-questionnaires: manual data entry Interviews: manual data entry Clinical examination:

	manual data entry Biological examination: direct data entry
Quality procedure(s) used	Coherence request during and after computer data entry. Missing data checked back to the original file and/or to a third. Subjects remainders for follow-up visits. Patients receive information about the use of their data.
Participant monitoring	Yes
Details on monitoring of participants	During 9 years
Links to administrative sources	Yes
Linked administrative sources (detail)	CépiDC, and RNIPP for the follow-up of vital status and medical death causes

Promotion and access

Promotion

Link to the document	http://www.hal.inserm.fr/DESIR
Description	List of publications in HAL
Link to the document	http://www.ncbi.nlm.nih.gov/pubmed/?term=%28DESIR+OR+D.E.S.I.R%29+AND+%28insulin+OR+diabetes%29+NOT+desir[author]
Description	List of publications in Pubmed

Access

Terms of data access (charter for data provision, format of data, availability delay)	Data utilization possible for academic teams and for industrials. Project demand - access to data and biobank Beverley Balkau: beverley.balkau@inserm.fr Fabienne Rakotozafy: fabienne.rakotozafy@irsa.asso.fr
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only